US Patent 11352348 Splicing modulator antibody-drug conjugates and methods of use
Patent 11352348 was granted and assigned to Eisai (company) on June, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+19 properties)
Infobox
Patent Inventor Names
Andrew Cook0
Dominic Reynolds0
Ermira Pazolli0
James Palacino0
Lihua Yu0
Megan Sheehan0
Michael Seiler0
Nathan Fishkin0
Nicholas Calandra0
Peter Smith0
Ping Zhu0
Shelby Ellery0
Shouyong Peng0
Silvia Buonamici0
Sudeep Prajapati0
Thiwanka Samarakoon0
Xiang Liu0
Yonghong Xiao0
Zhenhua Wu0
Edits on 9 Jun, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
Article (+466 characters)
US Patent 11352348 Splicing modulator antibody-drug conjugates and methods of use
Article
Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11352348
Date of patent
June 7, 2022
Patent application number
17247117
Date Filed
November 30, 2020
Patent primary examiner
Find more entities like US Patent 11352348 Splicing modulator antibody-drug conjugates and methods of use
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.